ArticleHemaSphere2022

Targeting the Second Transferrin Receptor as Emerging Therapeutic Option for β-Thalassemia Major.

Francesca Vinchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.